Patent 6410588 Issued on June 25, 2002. Estimated Expiration Date: March 6, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/454, Tricyclo ring system having the hetero ring as one of the cyclos514/456, Bicyclo ring system having the hetero ring as one of the cyclos (e.g., chromones, etc.)514/719Alicyclic ring
The application relates to the identification that cannabinoids, such as cannabidiol can be used to treat inflammatory diseases. Cannabinoids for use in treating inflammatory diseases, methods of treating inflammatory diseases and cannabinoids in combination with pharmaceutically acceptable carriers are claimed.
Other References
Holdcroft, A.; Smith, M.; Smith, B.; Hodgso, `Clinical trial experience with cannabinoids` CA 128:110760 (1997).
Formukong, E. A., `Analgesic and anti-inflammatory activity of constituents of Cannabis sativa L` CA 109:122008 (1988).
M. L. Barrett et al., Experientia, 42, 1986, pp. 452-453
M. L. Barrett et al., Biochemical Pharmacology, vol. 34, No. 11, 1985, pp. 2019-2024
E. A. Formukong et al, Phytotherapy Research, vol. 3, No. 6, 1989, pp. 219-231
Louis Lemberger, Annual Review of Pharmacology & Toxicology, vol. 20, 1980, pp. 151-172
Fred J. Evans, Pharmaceutical Sciences, vol. 3, 1997, pp. 533-537
Christine Gray, Pharmaceutical Journal, vol. 254, 1995, pp. 771-773
E. A. Formukong et al., Phytotherapy Research, vol. 5, 1991, pp. 258-261
A. T. Evans et al., Biochemical Pharmacology, vol. 36, No. 12, 1987, pp. 2035-2037
A. T. Evans et al., 122nd British Pharmaceutical Conference, Sep. 9-12, 1985, Journal of Pharmacy and Pharmacology, vol. 37, 1985, p. 43P
Journal of Pharmacy Technology, vol. 12, Nov./Dec. 1996, p. 294
Ladislav Volicer, American Family Physician, vol. 55, 1997, p. 1338
W. D. Lyman et al., Journal of Neuroimmunology, vol. 23, 1989, pp. 73-81
W. D. Lyman, Advances in Experimental Medicine and Biology, vol. 288, 1991, pp. 81-92
R. Elkin et al., Fed. Proc. Experimental Biology, vol. 46, 1987, p. 1378
C.N. Martyn et al., Lancet, vol. 345, Mar. 4, 1995, p. 579
Itzhak Wirguin et al., Immunopharmacology, vol. 28, 1994, pp. 209-214
J. Thornas Ungerleider et al., Advances in Alcohol and Substance Abuse, vol. 7, 1987, pp. 39-50
William A. Check, JAMA, vol. 241, 1979, p. 2476
David B. Clifford, Ann. Neurol., vol. 13, 1983, pp. 669-671
Donald P. Tashkin, Biochemistry and Physiology of Substance Abuse, vol. 3, 1991, pp. 41-70
B.J. Shapiro et al., Chest, vol. 71, 1977, pp. 558-560
S.J. Williams et al., Thorax, vol. 31, 1976, pp. 720-723
Donald P. Tashkin et al., American Review of Respiratory Disease, vol. 109, 1974, pp. 420-428
D.P. Tashkin et al., Am. Rev. Respir. Diseases, vol. 119, 1979, p. 82
J.P.R. Hartley et al., Br. J. Clin. Pharmacol., vol. 5, 1978, pp. 523-525
Bernhard Watzl et al., Int. J. Immuno. Pharmac., vol. 13, 1991, pp. 1091-1097
Raphael Mechoulam, Marijuna Chemistry, Metabolism and Clinical Effects, Academic Press, New York, 1973, pp. 1-99
Leo E. Hollister, Pharmacological Reviews, vol. 38, No. 1, 1986, pp. 1-20
William L. Dewey, Pharmacological Reviews, vol. 38, No. 2, 1986, pp. 151-177
D.R. Compton et al., Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach, Handbook of Experimental Pharmacology, vol. 118, 1996, pp. 83-158
A. Jacob et al., J. Chem. Soc., 1940, pp. 649-653
Roger Adams et al., J. Amer. Chem. Soc., vol. 62, 1940, pp. 2194-2196
R. Mechoulam et al., Tetrahedron, vol. 19, 1963, pp. 2073-2078
Raphael Mechoulam, Tetrahedron Letters, No. 12, 1967, pp. 1109-1111
Arthur C. Cope et al., J. Amer. Chem. Soc., vol. 87, pp. 3273-3275
T. Petrzilka et al., Helvetica Chimica Acta, vol. 50, No. 73-74, 1967, pp. 719-723
Science, vol. 169, Aug. 1970, pp. 611-612
L. Murphy et al, Marijuana/Cannabinoids, CRC Press, Boca Raton, 1992, pp. 1-33
J. Roberto Leite et al., Pharmacology, vol. 24, 1982, pp. 141-146
J. Clin. Psychiatry, vol. 56, Oct. 1995, pp. 485-486
Margaret S. Smith et al., Proc. Soc. Exp. Bio. Med., vol. 214, 1997, pp. 69-75
E.A. Formukong et al., Inflammation, vol. 12, No. 4, 1988, pp. 361-371
Ronald G. Coffey et al., Biochemical Pharmacology, vol. 52, 1996, pp. 743-751
Bernhard Watzl et al., Adv. Esp. Med. Biol., vol. 288, 1991, pp. 63-70
A.W. Zuardi et al., Psychopharmacology, vol. 104, 1991, pp. 260-26
March 6, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
